International collaboration to assess the risk of Guillain Barré Syndrome following Influenza A (H1N1) 2009 monovalent vaccines.
about
Enhancing vaccine safety capacity globally: A lifecycle perspectiveVaccine Adjuvants: from 1920 to 2015 and BeyondSafety assessment of adjuvanted vaccines: Methodological considerationsEvolution of primary care databases in UK: a scientometric analysis of research outputEnhancing the work of the Department of Health and Human Services national vaccine program in global immunization: recommendations of the National Vaccine Advisory Committee: approved by the National Vaccine Advisory Committee on September 12, 2013Frequently asked questions on seven rare adverse events following immunization.Surveillance systems and methods for monitoring the post-marketing safety of influenza vaccines at the Centers for Disease Control and Prevention.Risk of Guillain-Barré syndrome following pandemic influenza A(H1N1) 2009 vaccination in GermanyBig Data Usage Patterns in the Health Care Domain: A Use Case Driven Approach Applied to the Assessment of Vaccination Benefits and Risks. Contribution of the IMIA Primary Healthcare Working Group.Responding to vaccine safety signals during pandemic influenza: a modeling study.Risk of Guillain-Barré syndrome after exposure to pandemic influenza A(H1N1)pdm09 vaccination or infection: a Norwegian population-based cohort study.Guillain-Barré syndrome following the 2009 pandemic monovalent and seasonal trivalent influenza vaccination campaigns in Spain from 2009 to 2011: outcomes from active surveillance by a neurologist network, and records from a country-wide hospital diProspective influenza vaccine safety surveillance using fresh data in the Sentinel System.Assessing recording delays in general practice records to inform near real-time vaccine safety surveillance using the Clinical Practice Research Datalink (CPRD)Guillain-Barre syndrome following quadrivalent human papillomavirus vaccination among vaccine-eligible individuals in the United States.In silico analysis of autoimmune diseases and genetic relationships to vaccination against infectious diseases.The complementary roles of Phase 3 trials and post-licensure surveillance in the evaluation of new vaccines.The use of relative incidence ratios in self-controlled case series studies: an overview.Outcome of Guillain - Barré Syndrome in Children: A prospective cohort study in a tertiary hospital in Upper Egypt.The risks of risk aversion in drug regulation.Active surveillance for adverse events following immunization.Perspectives on the future of postmarket vaccine safety surveillance and evaluation.Evaluation of 'SAEFVIC', A Pharmacovigilance Surveillance Scheme for the Spontaneous Reporting of Adverse Events Following Immunisation in Victoria, Australia.Enhancing global vaccine pharmacovigilance: Proof-of-concept study on aseptic meningitis and immune thrombocytopenic purpura following measles-mumps containing vaccination.Population incidence of Guillain-Barré syndrome in parts of China: three large populations in Jiangsu province, 2008-2010.Influenza vaccines: Evaluation of the safety profile.
P2860
Q26782451-67FB0AEE-A141-4F66-AB7B-8F630A1EA749Q26783879-6160F7BC-58EF-4FC9-89F4-BD859F8568D4Q27013956-397E7203-25CD-4345-BA41-70C32C8FCB6BQ28552854-A9C1FC1F-7E38-449B-B828-8786CF0E6EFDQ28654939-3CBED3DC-642F-4853-B503-4321E73AE85BQ30234430-E7F76CF5-269F-4FC2-A3BD-6D06921673D6Q30249793-1D87DF13-B792-42B8-8609-758EF7ACAFEEQ30362413-E5E93E1C-EAA6-4500-A39E-DAC737E59425Q30365708-696B452F-C4F4-4EA0-9579-0C2B353AE94CQ30370076-5F8F9FC4-001B-4E59-801E-A9AF792D94B8Q30374961-0888598F-FD8F-417D-97F4-39A82F7F81EFQ30388367-91380A1E-E627-4769-B5F9-43E6301ADF9BQ31024252-04F213E9-F6BE-4E3A-90C7-6826C05BAF62Q33578378-BF534FE6-AC65-4F05-A7B5-4FD3041C85DFQ34271547-0C38EA6E-C1F3-4A85-84D5-07F728442C21Q34700616-5D3DF90B-6285-4D84-8773-2FB6A6F13002Q36131193-638C500C-DB4F-406B-A106-EFA3D7A9B473Q36143663-9D8AC5EB-906E-4A12-BDCC-31680D3CEDFDQ37613920-98C53730-F327-4B74-8895-863E7E020AE6Q38162718-BF8ADFB4-558D-4AFE-A704-26E6E1C06401Q38172268-2D29F7A3-8083-493D-8B50-E882349F627AQ38194216-01CFCACC-49D8-48D7-93F1-E8E7A0AC2BE0Q38877088-3C72E4FB-46D6-4D67-9A27-A3BC0B828F8EQ39350135-9170CB50-32DC-4607-A541-1CE0DE292B44Q44927841-6C768D7B-7050-4631-B3B1-8D4CC51D68BEQ49345779-56D83A80-A370-4DC3-9656-CBE1DBC24B16
P2860
International collaboration to assess the risk of Guillain Barré Syndrome following Influenza A (H1N1) 2009 monovalent vaccines.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
International collaboration to ...... 1N1) 2009 monovalent vaccines.
@ast
International collaboration to ...... 1N1) 2009 monovalent vaccines.
@en
type
label
International collaboration to ...... 1N1) 2009 monovalent vaccines.
@ast
International collaboration to ...... 1N1) 2009 monovalent vaccines.
@en
prefLabel
International collaboration to ...... 1N1) 2009 monovalent vaccines.
@ast
International collaboration to ...... 1N1) 2009 monovalent vaccines.
@en
P2093
P50
P1433
P1476
International collaboration to ...... 1N1) 2009 monovalent vaccines.
@en
P2093
Caitlin N Dodd
Claudia Vellozzi
Corinne de Vries
Francisco Gimenez-Sanchez
Genevieve Deceuninck
Global H1N1 GBS Consortium
Harald Heijbel
Hayley Hughes
Hector Izurieta
Jann Storsaeter
P304
P356
10.1016/J.VACCINE.2013.06.032
P407
P577
2013-06-14T00:00:00Z